How would you treat lymphoplasmacytic lymphoma (LPL) with a non-IgM paraprotein?  

Does your treatment approach differ from Waldenstrom's Macroglobulinemia?

Does the presence/absence of a MYD88 L265P and/or CXCR4 mutation change your treatment approach?



Answer from: Medical Oncologist at Academic Institution